Type B - Oscar Health, Inc. (OSCR) 20261031 Stock Analysis

📅 Oscar Health Key Upcoming Events

• November 05, 2026 Q3 2026 Earnings Release (Confirmed)
  • Description: Oscar Health has scheduled its third-quarter earnings conference call for November 5, 2026. The corresponding financial results are expected before the call. Investors will examine medical loss ratio (MLR), membership retention, operating profitability, and whether management maintains its upgraded 2026 operating income outlook of $500M-$700M.
• November 2026 2027 ACA Open Enrollment and Consumer Product Rollout (Estimated)
  • Description: Oscar’s recently introduced consumer health products and Lucie marketplace capabilities are expected to feature in its 2027 coverage enrollment campaign. The company’s specific rollout milestones remain subject to operational updates, while pricing, customer acquisition, and enrollment conversion will influence its next annual revenue base.

🏢 Step 1: Oscar Health Company Overview & Business Model

Q1-A1. What is Oscar Health?

• Company Name (Ticker): Oscar Health, Inc. (OSCR)
• Sector: Healthcare
• Exchange: NYSE
• Founded: 2012
• Listing Date: March 03, 2021
• Fiscal Year End: December
• Headquarters: United States, New York City
• CEO: Mark Bertolini (Founder: No)
• Market Cap: $9.36B
• Shares Outstanding: 308.33M
• Current Price: $30.37
• Annual Dividend Yield: ➖ Not applicable
• Ex-dividend Date: ➖ Not applicable
• As-of: October 31, 2026 (ET)

Q1-A2. How Does Oscar Health Make Money?

• ACA Health Insurance Premiums: Oscar primarily earns premiums by underwriting individual health insurance plans, especially through the Affordable Care Act (ACA) marketplace. Members and government subsidies fund premiums, while Oscar pays covered medical claims and retains the difference after administrative expenses, risk adjustments, and other operating costs.
• Insurance Technology and Consumer Engagement: Oscar operates digital enrollment, claims, care-navigation, and member-support infrastructure intended to lower administrative friction and improve customer experience. These capabilities primarily support its insurance economics rather than constituting an independent software subscription business of comparable size.
• Marketplace and Technology Expansion: Lucie Health Marketplace and the company’s broader technology initiatives seek to extend Oscar’s reach into healthcare shopping, distribution, and partner services. These activities provide potential future revenue diversification, but insurance premiums remain overwhelmingly dominant.

Q1-A3. Oscar Health’s Revenue Segments & Core Income Sources

• Net Premium Revenue — Approximately 98.2%: Net premiums contributed approximately $15.04B of the $15.32B trailing-12-month revenue through June 2026. Growth reflects membership expansion, premium pricing, and risk-adjustment effects. This is the company’s principal economic engine.
• Investment Income — Approximately 1.6%: Investment income contributed approximately $248.23M over the same period. Insurance reserves and invested assets generate interest and investment returns, providing supplementary profitability that depends partly on prevailing yields.
• Services and Other Revenue — Approximately 0.2%: Approximately $29.58M came from services and other activities. Although strategically relevant to Oscar’s technology and marketplace ambitions, this revenue remains economically small.
• Revenue Mix Conclusion: Oscar is fundamentally a health insurance underwriter with a technology-enabled operating model, not a primarily software-driven business. Medical claims, premium adequacy, membership growth, and risk-adjustment transfers determine most of its financial performance.

Q1-A4. Who Are Oscar Health’s Competitors?

• Direct ACA Insurer Competitors: Centene’s Ambetter business, UnitedHealthcare, Elevance Health, Molina Healthcare, and various regional insurers compete across individual health insurance markets. Their geographic availability and plan positioning vary by state.
• Legacy Incumbents: Large established insurers possess broader provider relationships, greater resources, and diversified insurance portfolios. Oscar attempts to differentiate through digital enrollment, consumer-friendly plan design, and an individual-market-focused operating model.
• Technology Competition: Digital insurance brokers and healthcare enrollment platforms compete with aspects of Oscar’s consumer acquisition and marketplace activities, although they typically do not assume the same medical underwriting risk.
• Strategic Position: Oscar is an early technology-focused challenger in the individual insurance market rather than the industry’s first insurer. Its growth strategy emphasizes a modern consumer interface, specialized ACA expertise, and operating efficiency instead of competing solely through the lowest premium.

Q1-A5. What Problem Does Oscar Health Solve?

• Complex Insurance Shopping: Individuals often struggle to compare premiums, deductibles, provider networks, and coverage limitations. Oscar seeks to simplify insurance selection through digital shopping and plan-navigation tools.
• Fragmented Healthcare Experiences: Traditional insurance processes can involve complicated claims, disconnected provider information, and difficult customer support. Oscar integrates digital support and care-navigation functions to reduce these frictions.
• Coverage for Flexible Workers: Individuals moving among employment arrangements, gig work, self-employment, and retirement need portable coverage outside employer-sponsored plans. Oscar concentrates on the ACA individual market serving this demand.
• Economic Limitation: Better customer experience does not automatically create superior underwriting margins. Oscar still faces medical-cost inflation, adverse selection, regulated minimum medical spending requirements, and competitive premium pricing.

Q1-A6. Oscar Health Key Milestones: Past 12 Months

• May 06, 2026 Q1 2026 Earnings Release
  • Description: Oscar announced strong first-quarter financial results and reaffirmed its 2026 outlook, demonstrating improved earnings performance following the difficult underwriting conditions experienced in 2025.
• August 06, 2026 Q2 2026 Earnings Release and Guidance Increase
  • Description: Revenue reached $4.88B, up approximately 70.4% year over year, while operating income reached $388.64M compared with a $230.48M operating loss. Management increased full-year operating income guidance to $500M-$700M, supported by improved claims experience and administrative efficiency.
• September 16, 2026 Investor Day and Consumer Healthcare Strategy
  • Description: Oscar outlined plans to strengthen its individual-market insurance franchise and expand the Lucie Health Marketplace. The strategy emphasizes consumer choice, technology-enabled distribution, and the development of a broader healthcare engagement ecosystem.
• September 18, 2026 Thrive Capital Completes Share Distribution
  • Description: Thrive Capital-affiliated funds distributed approximately 6.3M Class A shares to limited partners. The transaction was an in-kind distribution rather than an issuer capital raise or a direct sale by Joshua Kushner. Affiliated holders retained approximately 67% of combined voting power, preserving concentrated control.
• October 20, 2026 Introduced New Consumer Health Products
  • Description: Oscar unveiled additional consumer-oriented health products, reinforcing its effort to differentiate insurance coverage through digital experiences and expanded consumer choice. Commercial success will depend on enrollment conversion and sustainable underwriting economics.

Q1-A7. Step 1 Key Takeaways

• Step 1 Summary: Oscar has developed a rapidly growing, technology-enabled ACA insurance franchise supported by almost 3 million members and improving underwriting economics. Its greatest opportunity is profitable individual-market expansion, while its principal weakness remains exposure to medical-cost volatility and healthcare policy.

🌲 Step 2: Oscar Health’s Economic Moat, Market Size & Scalability

Q2-A1. Does Oscar Health Have a Durable Economic Moat?

• Technology and Data Assets: Oscar’s proprietary insurance technology supports enrollment, claims administration, consumer engagement, and underwriting analytics. Its operating data and healthcare workflows provide efficiency advantages, although major incumbents can invest heavily in comparable capabilities.
• Network Effects: A larger membership base can improve provider contracting relevance and data quality, but insurance does not possess the powerful direct network effects characteristic of dominant digital marketplaces.
• Switching Costs: Annual plan enrollment cycles and comparable ACA offerings limit structural customer lock-in. Provider continuity, familiarity, and satisfaction may improve retention, but consumers can switch insurers when premiums or networks become unattractive.
• Brand and Customer Experience: Consumer-focused design provides differentiation, although independently established customer advocacy advantages sufficient to demonstrate a durable pricing premium are limited.
• Pricing Power: Premium increases are constrained by competition, affordability, ACA regulations, and minimum medical loss requirements. Oscar’s primary opportunity is more accurate risk pricing and lower administrative costs rather than unconstrained premium increases.

Q2-A2. How Big Is Oscar Health’s Market? (TAM)

• Total Addressable Market: The United States ACA marketplace represents a substantial annual premium pool, with marketplace enrollment reaching tens of millions of people in recent coverage years. Oscar’s relevant opportunity is the portion of this market available in its licensed states and service areas.
• Market Growth: Individual coverage demand benefits from employment flexibility, gig work, healthcare cost inflation, and continued access to marketplace subsidies. However, policy changes and enrollment fluctuations make a fixed long-term market CAGR unreliable.
• Serviceable Market: Oscar’s nearly 2.96M effectuated members at June 30, 2026 demonstrate meaningful penetration, but expansion opportunities depend on state-level regulations, provider networks, competition, and capital requirements.
• Long-Term Opportunity: The potential marketplace and distribution opportunity exceeds Oscar’s current insurance customer base, but expanding addressable demand does not automatically translate into equivalent revenue growth or shareholder value.

Q2-A3. How Real Is Oscar Health’s TAM? (Quality Check)

• Willingness to Pay: Health coverage is essential, supporting recurring demand, but buyers remain highly sensitive to after-subsidy premiums and expected out-of-pocket costs.
• Market Structure: The ACA market is competitive and geographically fragmented. Regional insurer positioning, provider-network quality, and state-specific risk pools can determine market share.
• Regulatory Barriers: Insurance licenses, solvency requirements, provider networks, actuarial capabilities, and regulatory oversight create substantial entry barriers.
• Profitability Ceiling: Insurance underwriting carries structurally thinner sustainable margins than high-margin software businesses. Even strong customer growth can produce disappointing returns if medical claims rise faster than premiums.

Q2-A4. Can Oscar Health Keep Expanding Its Market?

• Penetration Opportunity: Membership increased from approximately 2.03M to 2.96M year over year as of June 2026, representing approximately 46.2% growth. The company can expand further within eligible geographies and through competitive plan offerings.
• Geographic Scalability: Expansion is primarily domestic because US insurance regulations, reimbursement structures, and provider networks are not readily transferable internationally.
• Operating Scalability: Digital infrastructure can accommodate more members with relatively modest incremental administrative expense, as demonstrated by improvements in the SG&A expense ratio.
• Variable Cost Constraint: Medical claims scale with insured membership and utilization. Consequently, Oscar cannot achieve the near-zero marginal cost economics available to pure software platforms.
• Platform Optionality: Lucie and technology-driven distribution could improve customer acquisition efficiency and create complementary revenue streams, but the current financial contribution remains limited.

Q2-A5. Step 2 Key Takeaways

• Scoring Rationale:
  • Economic Moat (6/10): Specialized ACA capabilities and technology support differentiation, but switching costs and pricing power remain constrained.
  • Market Size (5/5): The substantial US individual insurance market offers significant expansion opportunities.
  • Market Quality·Profitability (5/7): Essential recurring demand and regulatory barriers are attractive, but medical claims and competitive pricing limit margins.
  • Market Penetration·Scalability (6/8): Rapid membership growth and administrative leverage support expansion, although insurance underwriting remains capital-intensive.
• 📊 Step 2 Score: 22/30 pts (Economic Moat 6/10 + Market Size 5/5 + Market Quality·Profitability 5/7 + Market Penetration·Scalability 6/8)
• Step 2 Summary: Oscar benefits from substantial market demand and increasingly efficient operations, but its competitive advantages are less durable than those of scalable software platforms.

🚀 Step 3: How Fast Is Oscar Health Growing? Hyper-Growth Metrics

Q3-A1. How Fast Is Oscar Health Growing? (Revenue Trajectory)

• Growth Reaccelerated Sharply: Revenue increased from $9.18B in FY2024 to $11.70B in FY2025, a 27.5% gain, while trailing-12-month revenue through June 2026 reached approximately $15.32B, up 42.8% against the comparable prior-year period. The acceleration reflects stronger membership growth and premium pricing.
• Quarterly Growth Remains Exceptional: Q1 2026 revenue was approximately $4.65B, compared with approximately $3.05B in Q1 2025, implying roughly 52.5% YoY growth. Q2 revenue of $4.88B increased approximately 70.4% YoY and 5.0% sequentially from Q1.
• Growth-Curve Position: Oscar is experiencing a renewed expansion phase after FY2025’s comparatively slower growth. Nevertheless, the approximately 60% FY2026 revenue growth implied by current estimates should not be extrapolated indefinitely because annual enrollment and premium repricing create substantial changes in growth rates.
• Acceleration Conclusion: Revenue growth has accelerated across the latest comparable quarters, supported by membership expansion and stronger premium revenue. The critical question is whether this growth can remain profitable after favorable claims experience normalizes.

Q3-A2. Oscar Health’s Key Growth Metrics

• Selected Industry Indicators: Effectuated membership, medical loss ratio, and administrative expense ratio best explain growth quality for an ACA-focused insurer because they jointly measure customer scale, underwriting discipline, and operating efficiency.
• Effectuated Membership: Oscar reported 2.96M members at June 30, 2026, compared with 2.03M a year earlier, an increase of approximately 46.2%. The expansion supports premium growth but also increases the company’s exposure to variations in healthcare utilization.
• Medical Loss Ratio: Q2 2026 MLR improved to 79.2% from 91.1% in Q2 2025. The improvement reflects disciplined pricing and favorable reserve development, including $164M of favorable prior-period reserve adjustments.
• Administrative Efficiency: Q2 SG&A expense ratio declined to 14.2% from 18.7%, showing that administrative costs grew more slowly than revenue.
• Growth Quality: Membership and premium growth have translated into improved underwriting profitability, but the sustainability of medical-cost assumptions is more important than headline enrollment alone.

Q3-A3. Are Oscar Health’s Unit Economics Improving?

• Underwriting Economics: The Q2 2026 MLR of 79.2% and SG&A ratio of 14.2% indicate improved operating economics. However, the MLR improvement includes favorable reserve development and should not be treated entirely as recurring.
• Operating Margin Improvement: Q2 operating margin reached approximately 8.0%, compared with approximately -8.0% one year earlier. This sharp improvement demonstrates positive operating leverage.
• Rule of 40 Applicability: The Rule of 40 is designed mainly for software businesses and is not a reliable profitability benchmark for health insurers because premium revenue includes substantial medical claims obligations.
• Customer Acquisition Economics: Oscar has not established a comparable public LTV/CAC series sufficient to verify a 3.0x threshold. Membership growth and SG&A leverage provide stronger observable evidence of improved acquisition and servicing efficiency.
• Unit Economics Conclusion: Unit economics have improved materially, but a durable assessment requires examining normalized claims costs, reserve development, and performance across multiple underwriting periods.

Q3-A4. Step 3 Key Takeaways

• Scoring Rationale:
  • Revenue Growth Acceleration (10/12): Revenue growth accelerated sharply during the first half of 2026, though premium repricing and membership seasonality constrain extrapolation.
  • Sector-Specific Growth Metrics (9/10): Membership expansion, MLR improvement, and lower administrative ratios provide strong operating evidence.
  • Unit Economics·Margin (5/8): Underwriting profitability improved substantially, but favorable reserve development and uncertain long-term margin durability limit conviction.
• 📊 Step 3 Score: 24/30 pts (Revenue Growth Acceleration 10/12 + Sector-Specific Growth Metrics 9/10 + Unit Economics·Margin 5/8)
• Step 3 Summary: Oscar’s growth reacceleration is supported by measurable improvements in enrollment and insurance operating efficiency. Sustained profitability depends on maintaining disciplined medical-cost assumptions.

💪 Step 4: Oscar Health’s Profit Potential & Free Cash Flow

Q4-A1. Can Oscar Health Turn Growth Into Profit?

• Profitable Operating Inflection: Oscar reported $388.64M of Q2 2026 operating income versus a $230.48M loss in Q2 2025. First-half operating income reached approximately $1.09B compared with $66.64M in the prior-year period.
• Earnings Recovery: First-half 2026 net income attributable to Oscar reached approximately $1.04B, compared with $46.91M in first-half 2025.
• Guidance Improvement: Management raised its FY2026 operating income outlook from $250M-$450M to $500M-$700M, while maintaining revenue guidance of $18.7B-$19.0B.
• Seasonality and Normalization: First-half operating income already exceeded the full-year guidance range, demonstrating the importance of second-half claims seasonality and expected medical costs. The first-half margin must not be annualized mechanically.
• Operating Leverage Conclusion: The company has demonstrated genuine administrative leverage, but normalized full-year operating profitability is substantially lower than the exceptional first-half run rate.

Q4-A2. Does Oscar Health Generate Free Cash Flow?

• Reported Cash Generation: Trailing operating cash flow through June 2026 was approximately $4.42B, with approximately $38.63M of capital expenditures, resulting in mechanically calculated free cash flow of approximately $4.38B.
• Insurance Cash Flow Distortion: Premium collection timing, medical claims payable, restricted insurance assets, and risk-adjustment settlements can cause operating cash flow to deviate substantially from distributable economic earnings.
• Capital Requirements: Regulated insurance subsidiaries must maintain sufficient statutory capital and liquidity. Cash supporting policyholder obligations cannot be valued as freely distributable shareholder cash.
• Self-Funding Assessment: Positive earnings, investment assets, and operating liquidity support expansion, but the headline free cash flow figure overstates the amount potentially available for unrestricted reinvestment or shareholder distributions.
• Capital Efficiency Conclusion: Oscar’s financing position has improved, but sustainable normalized underwriting earnings and available statutory capital are more meaningful than conventional free cash flow yield.

Q4-A3. Step 4 Key Takeaways

• Scoring Rationale:
  • Operating Leverage·Path to Profit (6/8): Strong operating profitability and improved guidance establish an earnings inflection, tempered by claims seasonality and reserve benefits.
  • FCF·Capital Efficiency (5/7): Reported cash generation is substantial, but insurance working-capital timing and statutory restrictions limit its economic interpretation.
• 📊 Step 4 Score: 11/15 pts (Operating Leverage·Path to Profit 6/8 + FCF·Capital Efficiency 5/7)
• Step 4 Summary: Oscar has moved beyond a purely speculative profitability thesis. However, investors should value the company primarily through sustainable underwriting earnings rather than unusually large insurance-related cash inflows.

👔 Step 5: Oscar Health Management & Shareholder Alignment

Q5-A1. Who Leads Oscar Health? (Founder & Management)

• Leadership: Mark Bertolini serves as CEO and brings extensive managed-care leadership experience, including his prior tenure leading Aetna.
• Founder Participation: Oscar was co-founded by Joshua Kushner, Mario Schlosser, and Kevin Nazemi. Kushner remains Vice Chair and a significant controlling shareholder, while Schlosser continues to participate as a director.
• Strategic Vision: Management seeks to position Oscar as a consumer-focused insurance and healthcare marketplace company rather than a conventional carrier.
• Guidance Execution: The August 2026 increase in operating income guidance provides concrete evidence of better-than-previously-expected underwriting performance.
• Credibility Limitations: The company’s FY2025 loss and pronounced insurance earnings volatility demonstrate that achieving consistent multi-year profitability remains an important execution challenge.

Q5-A2. Is Oscar Health’s Management Aligned With Shareholders?

• Founder Control: Following Thrive Capital’s September 2026 distribution, Kushner-affiliated holdings represented approximately 67% of combined voting power. This reinforces long-term founder influence but limits minority shareholders’ ability to change corporate governance.
• Insider Transaction Evidence: Dedicated insider transaction records show substantial selling during 2026. CEO Mark Bertolini sold approximately 1.24M shares on June 25 and 1.21M shares on June 23. Director Mario Schlosser also sold approximately 750,000 shares on August 18.
• Additional Insider Sales: CFO Richard Scott Blackley sold 28,869 shares on September 3, while Chief Accounting Officer Victoria Baltrus sold 958 shares on the same date. Some reported sales were conducted under Rule 10b5-1 trading plans, limiting the usefulness of sales alone as an indicator of executives’ expectations.
• Aggregate Insider Flow: A trailing-12-month transaction compilation showed approximately $150.01M of reported sales against $11.92M of purchases, indicating materially net-negative disclosed transaction value. These values include transaction types requiring consideration of ownership structures and filing footnotes.
• Shareholder Dilution: Shares outstanding increased approximately 17.37% year over year. Share-based compensation, issuance activity, and capital structure changes therefore warrant close attention when assessing per-share shareholder returns.
• Governance Conclusion: Significant founder ownership creates economic alignment, but concentrated voting control, sizable insider selling, and dilution reduce confidence that minority shareholders participate proportionately in operating growth.

Q5-A3. Step 5 Key Takeaways

• Scoring Rationale:
  • Founder Management·Vision (5/8): Experienced management and founder involvement support execution, although the CEO is not a founder and historical results remain uneven.
  • Alignment·Accountability (4/7): Founder ownership supports long-term incentives, but concentrated voting power, substantial sales, and dilution weigh on minority-shareholder alignment.
• 📊 Step 5 Score: 9/15 pts (Founder Management·Vision 5/8 + Alignment·Accountability 4/7)
• Step 5 Summary: Oscar benefits from experienced insurance leadership and continued founder commitment, but governance concentration and meaningful shareholder dilution offset some of these advantages.

⛵ Step 6: Oscar Health Market Flow & Sentiment

Q6-A1. Analyst Consensus vs Oscar Health Guidance

• Revenue Expectations: FY2026 management revenue guidance stands at $18.7B-$19.0B, with a midpoint of $18.85B. Compiled analyst expectations of approximately $18.73B are slightly below that midpoint, suggesting that the current revenue outlook is broadly supported.
• Earnings Expectations: Management’s FY2026 operating income guidance midpoint is $600M, while compiled annual EPS estimates are approximately $1.94. These measures are not directly interchangeable because operating income precedes financing, taxes, and per-share adjustments.
• 2027 Expectations: Compiled estimates imply approximately $20.78B of revenue and $2.22 EPS for FY2027, corresponding to approximately 11% revenue growth and 14% EPS growth relative to FY2026 consensus.
• Analyst Positioning: The consensus rating remains Hold, with an average 12-month price target of approximately $36.40. Estimates indicate potential appreciation but also reflect uncertainty around the durability of underwriting earnings.
• Sentiment Assessment: August’s guidance increase improved the fundamental outlook, while subsequent estimate distributions suggest that the market is balancing strong near-term results against slower expected growth in 2027.

Q6-A2. What Is Oscar Health’s Short Interest?

• Short Interest: Approximately 18.29M shares were sold short in the latest reported period, equivalent to approximately 6.94% of the public float.
• Days to Cover: The short-interest ratio was approximately 3.35 trading days, indicating meaningful bearish positioning but not an exceptionally constrained short-covering environment.
• Institutional Ownership: Institutions held approximately 62.36% of shares, representing substantial professional-investor participation.
• Short Interest Trend: Reported short interest increased from approximately 17.77M shares in the preceding monthly observation to 18.29M, a rise of about 2.9%.
• Market Structure Conclusion: Short positioning creates some potential for sharp reactions to earnings surprises, but the more important price drivers remain medical claims, enrollment trends, and earnings revisions.

Q6-A3. Step 6 Key Takeaways

• Scoring Rationale:
  • Consensus vs Guidance (2/3): Revenue expectations align reasonably with company guidance, but earnings normalization limits the strength of the positive surprise potential.
  • Supply·Short Interest (1/2): Institutional participation is substantial, while moderate short interest and dilution create mixed supply-and-demand conditions.
• 📊 Step 6 Score: 3/5 pts (Consensus vs Guidance 2/3 + Supply·Short Interest 1/2)
• Step 6 Summary: Market expectations are constructive but not uniformly bullish. Upcoming earnings and medical-cost disclosures will likely determine whether investors reward growth or emphasize underwriting risks.

🧨 Step 7: Oscar Health Catalysts & Price Triggers

Q7-A1. What Could Re-Rate Oscar Health Stock? (Next 12 Months)

• 1 Q3 2026 Earnings and Medical Loss Ratio
  • Timing: November 05, 2026.
  • Success Conditions: Oscar reports underwriting performance consistent with full-year guidance and demonstrates that medical-cost trends remain manageable without unusually large reserve benefits.
  • Failure Risk: Adverse claims development or higher expected fourth-quarter utilization could undermine projected profitability.
• 2 2027 Enrollment and Premium Pricing
  • Timing: Late 2026 through the first half of 2027.
  • Success Conditions: Competitive plan pricing produces strong membership retention and new enrollment without deterioration in expected medical margins.
  • Failure Risk: Higher unsubsidized premiums, adverse selection, or intensified competition cause membership losses or inadequate pricing.
• 3 Lucie Marketplace and Consumer Product Expansion
  • Timing: Throughout 2027.
  • Success Conditions: New consumer-facing capabilities generate measurable acquisition efficiencies or incremental partner revenue.
  • Failure Risk: Product adoption remains limited, leaving Oscar dependent on traditional insurance underwriting for nearly all earnings.

Q7-A2. Oscar Health’s Estimate Revision Trend

• 2026 Estimate Improvement: The August increase in operating income guidance supports a materially stronger profitability outlook than earlier in the year.
• Revenue Estimate Trajectory: FY2026 revenue expectations of approximately $18.73B are consistent with management guidance, while FY2027 expectations indicate a significant moderation in growth.
• EPS Revision Assessment: Current FY2026 and FY2027 EPS estimates of approximately $1.94 and $2.22 support a profitable forward trajectory. A comparable full 90-day analyst-by-analyst revision series was not established, limiting the ability to quantify recent upward revision breadth.
• Revision Catalyst: A sustained decline in normalized MLR combined with maintained enrollment would provide stronger support for additional EPS upgrades than headline premium growth alone.

Q7-A3. Step 7 Key Takeaways

• Scoring Rationale:
  • Catalyst Strength (3/3): Near-term earnings, annual enrollment, and new product initiatives provide identifiable catalysts with meaningful operating consequences.
  • Estimated Trend (1/2): Improved management guidance supports the earnings outlook, but a consistent 90-day upward analyst revision trend was not established.
• 📊 Step 7 Score: 4/5 pts (Catalyst Strength 3/3 + Estimated Trend 1/2)
• Step 7 Summary: Oscar faces several meaningful operating catalysts, with underwriting performance and 2027 membership economics likely to matter more than early marketplace monetization.

⚖️ Step 8: Is Oscar Health Fairly Valued? Valuation Analysis

Q8-A1. Oscar Health’s Key Valuation Multiples

• PS Ratio: 0.61x (fairly valued) — Low relative to many growth businesses, but insurance premium revenue carries substantial medical expense obligations.
• P/FCF Ratio: 2.14x (not applicable) — The calculated ratio reflects insurance-related operating cash timing and is not a reliable indicator of distributable free cash flow.
• P/OCF Ratio: 2.12x (not applicable) — Operating cash flow contains material policyholder-related and working-capital movements.
• EV/Sales Ratio: 0.38x (not applicable) — Enterprise-value comparisons are less meaningful for regulated insurers because financial assets and liabilities are integral to underwriting operations.
• EV/EBITDA Ratio: 8.77x (not applicable) — Conventional industrial enterprise-value metrics poorly capture insurance reserve obligations and investment-asset economics.
• EV/FCF Ratio: 1.32x (not applicable) — The denominator does not represent normalized unrestricted owner cash flow.
• Forward PE: 16.66x (fairly valued) — The multiple is reasonable if the company sustains profitable underwriting and mid-teens earnings growth.
• PEG Ratio: N/A (unverifiable)
• Scoring Rationale: Oscar’s forward earnings multiple appears broadly supportable relative to expected growth, although reserve development, earnings seasonality, and uncertain sustainable margins weaken the apparent attractiveness of cash-flow and revenue multiples. Insurance-specific normalized earnings are more informative than headline FCF.
• 📌 (1) Axis Q8-A1 Score: +1

Q8-A2. Oscar Health vs Peers: Valuation Comparison

• Multiple selection based on peer comparison: Forward P/E is the preferred metric because Oscar’s recent profitability supports an earnings-based comparison. Centene, Molina Healthcare, and other managed-care insurers provide relevant economic references, although their government-program exposure, scale, and margin profiles differ materially.
• Calculation of peer-to-peer deviation rate: N/A — A sufficiently comparable current peer mean using aligned forecast periods and normalized earnings definitions could not be established.
  • 🧮 Calculation Formula: ((Oscar forward P/E - comparable peer mean) / comparable peer mean) × 100; the missing comparable peer mean prevents a defensible numerical deviation.
• Scoring Rationale: Differences in medical-program exposure, underwriting profitability, risk adjustment, and forecast earnings normalization prevent a reliable mechanical peer premium or discount determination. No relative valuation advantage is assigned without a comparable denominator.
• 📌 (2) Axis Q8-A2 Score: 0

Q8-A3. What Is Oscar Health Worth in the Future? (Forward Valuation)

• Implied Future Multiple: At the October 30, 2026 closing price of $30.37, Oscar trades at approximately 13.68x compiled FY2027 EPS of $2.22. Using an analyst-assumed 11% cost of equity, the one-year-forward comparable earnings multiple is approximately 15.18x after bringing the FY2027 earnings benchmark back to the valuation date. For a further FY2028 illustration, assuming normalized EPS growth of 12% gives approximately $2.49, an undiscounted current-price/FY2028 EPS ratio of 12.20x and a two-year time-adjusted ratio of approximately 15.03x.
• Scoring Rationale: The implied forward earnings multiples are compatible with a moderately growing profitable insurer, provided that FY2026’s underwriting recovery persists. The FY2028 extension is an analytical scenario rather than reported management guidance or compiled consensus, and a substantial MLR deterioration would invalidate its earnings base.
• 📌 (3) Axis Q8-A3 Score: +1

Q8-A3-1. What Growth Hurdle Does the Market Demand From Oscar Health? (Forward Valuation Alternative)

• Scoring Rationale: Not applicable — The earnings-based FY2027 comparison and a stated FY2028 scenario support the primary forward valuation assessment.
• 📌 (3) Axis Q8-A3-1 Score: ➖

Q8-A4. Final Valuation Adjustment

• Scoring Rationale: Oscar’s operating recovery is partly supported by favorable prior-period reserve development, making headline earnings and cash conversion less reliable measures of recurring owner economics. A modest additional discount reflects this insurer-specific normalization uncertainty without duplicating the growth and multiple comparisons.
• 📌 (4) Axis Q8-A4 Score: -1

Q8-A5. Valuation Adjustment Score Calculation

• Calculation Process:
  • (1) Axis (Key Valuation Indicator): +1 pts (Fairly Valued)
  • (2) Axis (Peer-to-peer deviation rate): 0 pts (Comparable peer deviation unavailable)
  • (3) Axis (Justification of Growth): +1 pts (Time-adjusted forward earnings multiples broadly reasonable)
  • (4) Axis (Final adjustment): -1 pts (Earnings normalization uncertainty)
• 📊 Valuation Adjustment Score: A1 (+1) + A2 (0) + A3 (+1) + A4 (-1) = +1 pts
• Commentary: Oscar’s valuation is broadly consistent with a profitable insurer undergoing operational improvement rather than an extreme growth-stock premium. The investment case depends on recurring underwriting earnings and improved per-share economics.
• Step 8 Summary: Current valuation appears reasonably supported by normalized forward earnings, although insurer-specific reserve risk and incomplete peer comparability limit the evidence for a substantial discount to intrinsic value.

💀 Step 9: What Are the Risks of Oscar Health? Fatal Risks & Pre-Mortem

Q9-A1. Is Oscar Health Burning Cash & Diluting Shareholders?

• Liquidity Position: Reported cash and cash equivalents were approximately $8.56B against approximately $482.10M of debt in the latest compiled balance-sheet snapshot. However, substantial portions of insurer assets support policyholder obligations and statutory capital requirements rather than representing unrestricted parent-company liquidity.
• Cash Burn Assessment: Oscar generated positive first-half 2026 earnings and substantial reported operating cash flow. The evidence does not establish an immediate financing or insolvency threat.
• Confirmed Dilution: Total shares outstanding increased approximately 17.37% year over year. This materially exceeds the pace desirable for stable per-share compounding and means that operating earnings growth must be shared across a larger equity base.
• Dilution Consequences: Continued issuance can reduce EPS growth and dilute existing investors even as total company revenue and earnings increase. The share-count movement is a demonstrated shareholder risk rather than a hypothetical funding concern.
• Insider Supply: Large disclosed insider sales and Thrive’s distribution create potential secondary-market supply, although the Thrive transaction did not issue new company shares.

Q9-A2. Do Competition or Regulation Threaten Oscar Health?

• ACA Subsidy Policy: Oscar is highly exposed to US individual-market insurance rules. Changes in federal premium subsidies, eligibility, enrollment rules, or risk-adjustment formulas can materially alter affordability and the composition of its insured population.
• Medical Claims Volatility: Higher utilization, more severe member health conditions, or inaccurate pricing assumptions can quickly erode underwriting profitability. The historical swing in MLR demonstrates the financial sensitivity.
• Competitive Responses: Large insurers can compete through pricing, provider networks, marketing scale, and product breadth. Oscar’s digital capabilities may improve execution but do not eliminate competitive pressure.
• Regulatory Capital Requirements: State insurance regulators require adequate statutory capital, restricting the amount of cash that can be freely transferred to the public-company parent.
• Policy Concentration: Because nearly all revenue comes from insurance premiums, Oscar has limited financial diversification if the ACA individual market encounters major regulatory or enrollment disruptions.

Q9-A3. Oscar Health Pre-Mortem: What Could Go Wrong?

• 1 A medical-cost resurgence destroys expected underwriting margins: Oscar prices coverage for favorable claims trends, but higher utilization and adverse risk adjustment push actual medical costs beyond premium assumptions.
  • Early Warning Signal: Reported MLR persistently exceeds the revised FY2026 guidance range or management materially lowers its operating income forecast.
• 2 ACA affordability changes trigger unfavorable enrollment dynamics: Reduced subsidy support or higher customer contributions cause healthier members to leave while higher-cost customers remain, undermining the expected risk pool.
  • Early Warning Signal: Enrollment retention weakens while per-member medical costs rise despite premium increases.
• 3 Persistent share issuance undermines per-share earnings growth: Strong operating growth fails to translate into shareholder returns because dilution and equity-linked compensation increase the share denominator.
  • Early Warning Signal: Shares outstanding continue increasing at double-digit annual rates without comparable improvement in diluted EPS.

Q9-A4. Risk Adjustment Score

• Reason for Scoring: Oscar’s approximately 17.37% year-over-year increase in shares outstanding represents a material, already-realized dilution exposure that can continue to impair per-share value if issuance persists. The company’s earlier underwriting volatility adds a separate source of uncertainty around normalized earnings, while positive first-half profitability and substantial insurance-sector liquidity mitigate immediate funding risk.
• 📊 Risk Adjustment Score: -8 pts
• Step 9 Summary: The most consequential risks are continued shareholder dilution, underwriting volatility, and dependence on ACA market economics. Oscar’s improved profitability reduces near-term financial stress but does not eliminate these structural exposures.

🎯 Step 10: Oscar Health Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

• Investment Score Calculation Formula:
  • Step breakdown: S2 (22) + S3 (24) + S4 (11) + S5 (9) + S6 (3) + S7 (4) = 73 pts
  • Steps 2-7 Sum (73 pts) + Valuation Adjustment (+1 pts) + Risk Adjustment (-8 pts) = Investment Score 66 pts
• Investment Score & Rating: 66 pts (B Rating ⭐⭐⭐)
  • Commentary: Rapid enrollment growth, stronger underwriting profitability, and measurable administrative leverage support the investment case. However, concentrated governance, substantial dilution, and medical-cost sensitivity constrain its overall attractiveness despite a broadly reasonable valuation.

Q10-A2. Should You Buy Oscar Health? (Recommendation)

• Recommendation: Hold
  • Commentary: Oscar offers attractive exposure to individual health insurance growth and improving operating economics, but continued shareholder dilution and uncertainty surrounding normalized medical costs limit conviction at the prevailing valuation. Existing investors may retain exposure while monitoring underwriting quality, with selective new purchases better suited to more attractive entry prices.

Q10-A3. Investment Thesis in One Line

• Oscar Health combines rapid ACA membership growth with improving underwriting profitability, but shareholder dilution, medical-cost volatility, and dependence on healthcare policy constrain the long-term investment case.

Q10-A4. Oscar Health’s Price Trend & Key Drivers

• Stock Price Trend Over the Past 12 Months: Strong Recovery With Recent Consolidation 📈➡️ — Oscar shares gained approximately 60.6% over the trailing 52 weeks through October 30, 2026, trading within a $10.69-$35.01 range before closing at $30.37. The stock remained above its approximately $23.60 200-day moving average but below its $31.71 50-day moving average.
• August 06, 2026 Q2 Earnings and Improved 2026 Guidance
  • Description: Oscar reported sharp earnings improvement and raised its operating income outlook, reinforcing the recovery narrative. Strong first-half underwriting results and lower administrative expense ratios supported investor interest in the company’s earnings inflection.
  • Stock Price Reaction: Mixed Near-Term Trading ➡️ — The company entered a period of elevated trading and valuation reassessment around the earnings announcement. A sufficiently precise event-window price direction was not established to attribute a specific move to the release.
• September 2026 Investor Day and Shareholder Distribution
  • Description: Oscar introduced its expanded consumer marketplace strategy, while Thrive Capital’s distribution increased the number of shares held outside its affiliated funds without issuing new equity.
  • Stock Price Reaction: Volatile Consolidation ➡️ — Shares traded around the low-$30s during the late-summer period, reflecting an elevated valuation relative to earlier 2026 levels. The separate price effects of the strategic update and shareholder distribution cannot be isolated from broader trading.
• October 23, 2026 Sharp Weekly Pullback
  • Description: The stock experienced a significant decline during the final full trading week of October ahead of the next earnings report.
  • Stock Price Reaction: Sharp Decline 📉 — Shares closed at $30.99 on October 23, down approximately 7.0% that session, before stabilizing around $30-$31 during the following week.

Q10-A5. Action Plan

• Current Price: $30.37
• Buy Zone: $27.00 ($26.00–$28.00)
  • (1) Calculation of Fundamental Value: A conservative entry range is established below the $35.52 forward earnings-based target, with sufficient room for temporary earnings volatility and a margin of safety against underwriting uncertainty.
  • (2) Momentum Premium/Discount Application: The stock’s substantial recovery and positive long-term trend justify avoiding an excessively deep discount requirement. However, its elevated beta, recent consolidation, and shareholder dilution argue against paying an additional speculative momentum premium.
  • (3) Conclusion: The $26.00-$28.00 band, centered at $27.00, provides a more attractive balance between potential earnings upside and insurance-specific downside risks.
• Price Target: $35.52
• Expected Return: +17.0% (vs. current price)
  • 📍 Selected Valuation Metric: FY2027 forward diluted EPS × justified forward P/E — a normalized earnings approach is more economically appropriate for Oscar than headline operating cash flow or revenue multiples.
  • 🧮 Price Target Calculation Formula: FY2027 estimated diluted EPS $2.22 × target P/E 16.0x = $35.52
  • ⚓ Valuation Basis and Key Assumptions: The $2.22 FY2027 EPS estimate reflects compiled analyst expectations available before Q3 2026 results, rather than guaranteed earnings. A judgment-based 16.0x multiple reflects approximately mid-teens earnings growth, improving underwriting profitability, and the offsetting effects of medical-cost volatility and dilution. The current FY2027 multiple of approximately 13.68x is an undiscounted diagnostic, while the time-adjusted future valuation in Q8 incorporates the cost of equity. The 6-12-month target assumes earnings realization gradually supports the selected forward multiple rather than an immediate revaluation. The estimate is sensitive to medical loss ratio normalization, future dilution, and ACA enrollment policy.
• Conditions and timing for reaching price target: Over the next 6-12 months, the target becomes more plausible if the November 2026 earnings release confirms disciplined underwriting and subsequent 2027 enrollment disclosures demonstrate that profitable membership growth can continue without materially higher medical claims.
• Stop Loss: $22.50 ($22.00–$23.00)
• Action trigger upon catalyst achievement:
  • 1 Q3 earnings confirm favorable medical-cost trends
    • Description: Stable underwriting performance and maintained or increased full-year guidance would reinforce the sustainable earnings case. 👉 Maintain Holdings (Hold)
  • 2 2027 enrollment grows with stable expected medical margins
    • Description: Improved membership quality alongside growth could support additional earnings upside, especially if the share count stabilizes. 👉 Consider Buying Within Buy Zone (Buy)
  • 3 Lucie marketplace develops measurable recurring economic contribution
    • Description: Verified incremental revenue or customer acquisition efficiencies could improve the company’s earnings quality, although early product announcements alone are insufficient. 👉 Maintain Holdings (Hold)
• Action trigger upon risk realization:
  • 1 Medical loss ratio deteriorates persistently beyond guidance
    • Description: A sustained increase in claims costs would undermine normalized earnings assumptions and require reevaluation of fair value. 👉 Reduce Holdings (Sell)
  • 2 ACA policy changes materially weaken enrollment economics
    • Description: A significant reduction in affordability or deterioration of the covered risk pool would threaten the company’s principal growth engine. 👉 Reduce Holdings (Sell)
  • 3 Equity dilution continues above sustainable earnings growth
    • Description: Continued large increases in outstanding shares would weaken per-share compounding even if total operating income improves. 👉 Reassess Position (Hold)
• Customized Strategy Guide by Investment Preference:
  • Defensive Investors: Limit exposure until multiple earnings periods establish sustainable underwriting profitability and materially slower share dilution.
  • Neutral Investors: Maintain a moderate position and favor additions around the identified Buy Zone, with particular attention to MLR, enrollment quality, and diluted EPS.
  • Aggressive Investors: Consider staged entry during volatility, but size exposure conservatively given the stock’s elevated beta and dependence on insurance pricing and regulatory outcomes.

🕵️‍♂️ Deep Dive Analysis

Q1: Is Oscar Health’s Dependence on ACA Insurance and Medical Claims Its Biggest Weakness?

• Analysis: Approximately 98% of Oscar’s revenue comes from net insurance premiums, leaving the company highly dependent on a single regulated market. Medical costs can fluctuate with utilization, member health, reserve adjustments, and premium adequacy. Although digital infrastructure helps reduce administrative costs, its benefits cannot offset unlimited deterioration in the medical loss ratio. The sharp difference between 2025 and 2026 underwriting results demonstrates that profitability can change much faster than membership or revenue growth.
• Judgment: Negative — Oscar’s concentration in ACA underwriting remains its principal structural weakness despite improved operating execution.

Q2: Can Oscar Health’s Approximately 16.7x Forward P/E Be Justified by Its Earnings Recovery?

• Analysis: The forward multiple is reasonable for an insurer expected to grow revenue and earnings while improving administrative efficiency. However, normalized earnings must exclude unusually favorable reserve developments and account for claims seasonality. A 16.0x target multiple on FY2027 estimated diluted EPS provides a plausible 6-12-month valuation anchor without assuming software-like margins. A higher multiple would require stronger evidence of durable underwriting profitability and lower dilution.
• Judgment: Fairly Valued — The earnings recovery supports the current valuation, but the evidence does not establish an unusually large valuation discount.

Q3: Can Oscar Health Maintain Membership Growth After the 2026 Expansion Surge?

• Analysis: Membership increased approximately 46% year over year to 2.96M by June 2026, supporting a substantial increase in premium revenue. Growth of this magnitude may moderate as the comparison base expands and ACA enrollment patterns normalize. Future growth will depend on competitive plan prices, provider-network appeal, member retention, and the affordability of coverage after subsidies.
• Judgment: Cautiously Positive — Oscar has demonstrated strong customer acquisition capability, but sustainable growth should be assessed alongside member profitability rather than enrollment alone.

Q4: How Much of Oscar Health’s 2026 Profit Improvement Is Recurring?

• Analysis: The Q2 2026 MLR fell by 11.9 percentage points year over year, but the quarter benefited from approximately $164M of favorable prior-period reserve development. Operating income of $388.64M therefore reflects both improved current operating execution and favorable accounting-period developments. The upgraded full-year operating income guidance provides a more balanced normalization anchor than annualizing first-half results, which are affected by medical-cost seasonality.
• Judgment: Mixed — Administrative leverage appears genuine, while the precise recurring portion of the underwriting improvement requires additional earnings periods.

Q5: Does Oscar Health’s Technology Platform Create a Sustainable Competitive Advantage Against Larger Insurers?

• Analysis: Oscar’s digital capabilities can improve enrollment, care navigation, member service, and operating efficiency. Yet larger insurers have substantial technology budgets, provider relationships, and insurance data resources. Durable differentiation requires lower acquisition and servicing costs, better risk selection, or superior retention rather than consumer-interface improvements alone. The SG&A ratio decline provides encouraging evidence of scalability but is not sufficient to establish a permanent technology moat.
• Judgment: Moderately Positive — Oscar has useful technology-enabled efficiencies, but a decisive competitive moat has not been demonstrated.

Q6: Could Oscar Health’s Shareholder Dilution Offset Its Revenue and Earnings Growth?

• Analysis: Shares outstanding increased approximately 17.37% year over year, materially affecting per-share economics. Investors ultimately own claims on future profits divided among all outstanding shares. Even substantial total earnings growth can produce disappointing diluted EPS if equity issuance persists. Founder control may support strategic continuity, but it does not guarantee minority-shareholder protection from dilution.
• Judgment: Negative — Dilution is a demonstrated financial concern and should be monitored alongside normalized diluted EPS and equity compensation.

Q7: How Sensitive Is Oscar Health to Changes in ACA Premium Subsidies and Enrollment Policy?

• Analysis: ACA premium subsidies influence the affordability of individual coverage and therefore affect enrollment levels and the demographic composition of insured members. Less generous subsidies could reduce participation among price-sensitive consumers and alter the risk pool. Oscar may respond through premium pricing, plan design, and geographic adjustments, but such measures could sacrifice either membership or margins.
• Judgment: Negative — Regulatory dependence creates a material source of uncertainty that cannot be fully mitigated through operating efficiency.

Q8: Can Oscar Health Turn Lucie Marketplace Into a Meaningful Second Earnings Engine?

• Analysis: Lucie expands the company’s ability to participate in healthcare shopping and consumer engagement beyond direct underwriting. A successful marketplace could generate distribution-related economics while reducing dependence on insurance risk. However, services and other revenue currently represent only a small fraction of consolidated revenue. Meaningful valuation credit requires demonstrated monetization, customer adoption, and profitability rather than a broad strategic vision.
• Judgment: Neutral — The marketplace offers strategic optionality, but it is not yet a proven independent earnings engine.

Q9: Does Oscar Health’s Strong Operating Cash Flow Represent Freely Available Shareholder Value?

• Analysis: Trailing operating cash flow exceeded $4B, creating an apparently inexpensive cash-flow multiple. For a health insurer, premiums may be collected before medical claims are paid, while insurance reserves and regulated capital constrain the use of assets. Consequently, conventional operating cash flow less capital expenditure is not equivalent to cash distributable to equity holders. Sustainable underwriting profits, statutory surplus, and normalized capital generation offer more reliable valuation measures.
• Judgment: Neutral — Reported cash generation supports financial resilience, but headline FCF multiples should not be used as standalone evidence of deep undervaluation.

Q10: What Would Convince Investors That Oscar Health Has Become a Durable Earnings Compounder?

• Analysis: Oscar would need to demonstrate several consecutive underwriting periods of disciplined MLR, sustained administrative efficiency, stable or growing profitable membership, and materially reduced dilution. Earnings growth would need to translate into diluted EPS and economic capital accumulation rather than merely total revenue expansion. The November 2026 earnings release and subsequent 2027 enrollment results are important tests of whether the recent recovery is sustainable.
• Judgment: Conditionally Positive — Oscar has established a credible profitability recovery, but durable per-share earnings compounding remains unproven.